Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2025)
Monopar Therapeutics' (MNPR) quarterly Non-Current Assets came in at $254921.0 in Q4 2025, up 138.99% quarter-over-quarter from $106666.0 in Q3 2025.
Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Non-Current Assets across 9 years of filings, most recently posting $254921.0 for Q4 2025.
- Non-Current Assets for Q4 2025 came in at $254921.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $488859.0 (changed N/A YoY), and the FY2025 annual result was $254921.0, changed N/A from the prior year.
- Non-Current Assets came in at $254921.0 for Q4 2025 at Monopar Therapeutics, up from $106666.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $254921.0 in Q4 2025 to a low of $9102.0 in Q1 2025.
- The 4-year median for Non-Current Assets is $68858.0 (2021), against an average of $72803.1.
- Across the five-year window, Non-Current Assets climbed 22.52% in 2022 and slumped 79.35% in 2023, its largest moves.
- Monopar Therapeutics' Non-Current Assets stood at $68858.0 in 2021, then decreased by 11.08% to $61228.0 in 2022, then plunged by 79.35% to $12646.0 in 2023, then surged by 1915.82% to $254921.0 in 2025.
- The last three Non-Current Assets figures came in at $254921.0 (Q4 2025), $106666.0 (Q3 2025), and $118170.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 39.71 Mn |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - | 254,921.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 254,921.00 |
| Sep 30, 2025 | 106,666.00 |
| Jun 30, 2025 | 118,170.00 |
| Mar 31, 2025 | 9,102.00 |
| Dec 31, 2023 | 12,646.00 |
| Sep 30, 2023 | 25,088.00 |
| Jun 30, 2023 | 37,330.00 |
| Mar 31, 2023 | 49,376.00 |
| Dec 31, 2022 | 61,228.00 |
| Sep 30, 2022 | 72,889.00 |
| Jun 30, 2022 | 84,363.00 |
| Mar 31, 2022 | 53,694.00 |
| Sep 30, 2021 | 68,858.00 |
| Jun 30, 2021 | 68,858.00 |
| Mar 31, 2021 | 68,858.00 |
| Dec 31, 2020 | 68,858.00 |
| Sep 30, 2020 | 68,858.00 |
| Jun 30, 2020 | 73,050.00 |
| Mar 31, 2020 | 122,381.00 |
| Dec 31, 2019 | 122,381.00 |